(Tony Sifert, Headline USA) In accordance with the elite pivot on COVID policy as the 2022 midterm elections loom, the University of Virginia has issued a call for 15,000 people to participate in a study of the effectiveness of the hitherto-controversial drugs fluvoxamine and ivermectin, according to a report by NBC-12.
Participants “have to be over 30-years-old, test positive for COVID-19 within the past 10 days, and have at least two symptoms like fever, fatigue, body aches, loss of taste or smell,” NBC-12 reported.
“If we can find drugs that are currently FDA approved, cheap, and readily available throughout the world I think that really gets us much closer to being able to turn COVID-19 into a mild illness where people can kind of get therapy,” principal investigator Dr. Patrick Jackson said.
Fluvoxamine and ivermectin were specifically chosen “because there have been signs of helpfulness,” Dr. Jackson continued. “[V]ery high doses of ivermectin will stop many viruses from replicating.”
This novel idea would have been mercilessly crushed by the biomedical security state last year, but the likes of Covid Czar Anthony Fauci began making pro-ivermectin noises from a White House podium as recently as early January.
A similar study was launched last summer by Duke University after “some early studies that showed that it could potentially be helpful with COVID-19,” according to a Jan. 22 report in the Raleigh News & Observer.
That study has now been expanded to include higher doses of ivermectin, the Duke University Health System reported.
“Data from modeling studies, published clinical research, and community interest support investigating multiple doses and durations of ivermectin,” said Dr. Adrian Hernandez, the study’s principal investigator. “This expansion will provide valuable data on the role of ivermectin.”
Not to be deterred, leftist reporters on Twitter are pushing a JAMA Network study, published Feb. 18, which purports to show that “a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.”
